| Q34749384 | APOBEC3G-Augmented Stem Cell Therapy to Modulate HIV Replication: A Computational Study |
| Q37980423 | Achieving a cure for HIV infection: do we have reasons to be optimistic? |
| Q55383943 | CRISPR therapeutic tools for complex genetic disorders and cancer (Review). |
| Q47236016 | Cell and Gene Therapy for HIV Cure |
| Q34647798 | Combinatorial anti-HIV gene therapy: using a multipronged approach to reach beyond HAART |
| Q43564279 | Comparative Analysis of Tat-Dependent and Tat-Deficient Natural Lentiviruses |
| Q38800411 | Conditional Cytotoxic Anti-HIV Gene Therapy for Selectable Cell Modification |
| Q38032363 | Developing strategies for HIV-1 eradication |
| Q38777152 | Development of Lentiviral Vectors Simultaneously Expressing Multiple siRNAs Against CCR5, vif and tat/rev Genes for an HIV-1 Gene Therapy Approach |
| Q52718314 | Differential impact of transplantation on peripheral and tissue-associated viral reservoirs: Implications for HIV gene therapy. |
| Q35567289 | Eradication of human immunodeficiency virus from brain reservoirs |
| Q35693594 | Finding Fusin/CXCR4, the First "2nd Receptor" for HIV Entry |
| Q52590505 | Genome editing for the treatment of tumorigenic viral infections and virus-related carcinomas. |
| Q38783049 | HIV-1 adaptation to low levels of CCR5 results in V3 and V2 loop changes that increase envelope pathogenicity, CCR5 affinity and decrease susceptibility to Maraviroc |
| Q36976156 | HIV-1 transcription and latency: an update |
| Q52803378 | HIV-Specific T Cells Generated from Naive T Cells Suppress HIV In Vitro and Recognize Wide Epitope Breadths. |
| Q42925261 | Hematopoietic cell transplantation and HIV cure: where we are and what next? |
| Q36295174 | Hematopoietic cell transplantation with cord blood for cure of HIV infections |
| Q37965728 | Immunomodulation using agonists and antagonists: potential clinical applications |
| Q90290758 | Immunotherapy in People With HIV and Cancer |
| Q36437368 | Impact of sustained RNAi-mediated suppression of cellular cofactor Tat-SF1 on HIV-1 replication in CD4+ T cells. |
| Q91618349 | Improvement in Hepatic Fibrosis Biomarkers Associated With Chemokine Receptor Inactivation Through Mutation or Therapeutic Blockade |
| Q27021524 | Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions |
| Q33611645 | Induction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy |
| Q36923006 | Inhibition of HIV replication in vitro by clinical immunosuppressants and chemotherapeutic agents |
| Q35993707 | Interplay between HIV-1 and Host Genetic Variation: A Snapshot into Its Impact on AIDS and Therapy Response. |
| Q38071699 | Is specific HIV eradication from the brain possible or needed? |
| Q36067042 | Lack of viral control and development of combination antiretroviral therapy escape mutations in macaques after bone marrow transplantation |
| Q27318042 | Lentivirus-mediated Gene Transfer in Hematopoietic Stem Cells Is Impaired in SHIV-infected, ART-treated Nonhuman Primates |
| Q37661792 | Loss of immune homeostasis dictates SHIV rebound after stem-cell transplantation |
| Q36613666 | Multilineage polyclonal engraftment of Cal-1 gene-modified cells and in vivo selection after SHIV infection in a nonhuman primate model of AIDS |
| Q35652119 | RNA interference approaches for treatment of HIV-1 infection |
| Q34597465 | Synergistic combinations of the CCR5 inhibitor VCH-286 with other classes of HIV-1 inhibitors |
| Q38856090 | T-cell therapies for HIV: Preclinical successes and current clinical strategies. |
| Q36010933 | Thirty Years with HIV Infection-Nonprogression Is Still Puzzling: Lessons to Be Learned from Controllers and Long-Term Nonprogressors |